Pharmacotherapy Considerations in the Management of Transgender Patients: A Brief Review
Identifieur interne : 000D89 ( Main/Exploration ); précédent : 000D88; suivant : 000D90Pharmacotherapy Considerations in the Management of Transgender Patients: A Brief Review
Auteurs : Bryan M. Bishop [États-Unis]Source :
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy [ 0277-0008 ] ; 2015-12.
Abstract
Transgender and transsexual individuals have unique health care needs and risks compared with the population at large. It is estimated that 1 in 100,000 individuals in the United States is a transgender woman and 1 in 400,000 is a transgender man, although these estimates of prevalence are likely conservative. Transgender individuals are at an increased risk of tobacco, alcohol, and substance abuse; they have an increased lifetime suicide attempt risk; and they are more likely to experience significant stressors in their lives. Transgender patients may elect to transition their appearance to the gender with which they identify. Hormone treatment (and possibly sex reassignment surgery) is a significant part of this transition, and pharmacists must understand the pharmacotherapeutic principles involved so they can better recommend therapeutic agents, provide dosing recommendations, and anticipate and manage adverse effects. It is critical to be culturally sensitive when providing care for transgender patients including using their preferred gender identity, preferred names, and preferred pronouns. It is also essential to be able to identify transgender and transsexual patients correctly within electronic health records to ensure that appropriate care and monitoring are provided. For pharmacists, this means they should know the biologic sex for performing calculations such as creatinine clearance and to prevent teratogenic agents from reaching a transgender or transsexual man who could be pregnant or is capable of becoming pregnant. Promoting knowledge of transgender health issues will enable pharmacists to provide better, more holistic care to their transgender patients.
Url:
DOI: 10.1002/phar.1668
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001632
- to stream Istex, to step Curation: 001559
- to stream Istex, to step Checkpoint: 000109
- to stream Main, to step Merge: 000D90
- to stream Main, to step Curation: 000D89
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pharmacotherapy Considerations in the Management of Transgender Patients: A Brief Review</title><author><name sortKey="Bishop, Bryan M" sort="Bishop, Bryan M" uniqKey="Bishop B" first="Bryan M." last="Bishop">Bryan M. Bishop</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:984FBAFEAB0F1039C9CB16FEEA603ECD8A3A3ABA</idno><date when="2015" year="2015">2015</date><idno type="doi">10.1002/phar.1668</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-GH6J0RJZ-J/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001632</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001632</idno><idno type="wicri:Area/Istex/Curation">001559</idno><idno type="wicri:Area/Istex/Checkpoint">000109</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000109</idno><idno type="wicri:doubleKey">0277-0008:2015:Bishop B:pharmacotherapy:considerations:in</idno><idno type="wicri:Area/Main/Merge">000D90</idno><idno type="wicri:Area/Main/Curation">000D89</idno><idno type="wicri:Area/Main/Exploration">000D89</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Pharmacotherapy Considerations in the Management of Transgender Patients: A Brief Review</title><author><name sortKey="Bishop, Bryan M" sort="Bishop, Bryan M" uniqKey="Bishop B" first="Bryan M." last="Bishop">Bryan M. Bishop</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Ohio</region></placeName><wicri:cityArea>Pharmacy Practice, University of Toledo College of Pharmacy, Toledo</wicri:cityArea></affiliation><affiliation wicri:level="1"><country wicri:rule="url">États-Unis</country></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy</title><title level="j" type="alt">PHARMACOTHERAPY: THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY</title><idno type="ISSN">0277-0008</idno><idno type="eISSN">1875-9114</idno><imprint><biblScope unit="vol">35</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1130">1130</biblScope><biblScope unit="page" to="1139">1139</biblScope><biblScope unit="page-count">10</biblScope><date type="published" when="2015-12">2015-12</date></imprint><idno type="ISSN">0277-0008</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0277-0008</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Transgender and transsexual individuals have unique health care needs and risks compared with the population at large. It is estimated that 1 in 100,000 individuals in the United States is a transgender woman and 1 in 400,000 is a transgender man, although these estimates of prevalence are likely conservative. Transgender individuals are at an increased risk of tobacco, alcohol, and substance abuse; they have an increased lifetime suicide attempt risk; and they are more likely to experience significant stressors in their lives. Transgender patients may elect to transition their appearance to the gender with which they identify. Hormone treatment (and possibly sex reassignment surgery) is a significant part of this transition, and pharmacists must understand the pharmacotherapeutic principles involved so they can better recommend therapeutic agents, provide dosing recommendations, and anticipate and manage adverse effects. It is critical to be culturally sensitive when providing care for transgender patients including using their preferred gender identity, preferred names, and preferred pronouns. It is also essential to be able to identify transgender and transsexual patients correctly within electronic health records to ensure that appropriate care and monitoring are provided. For pharmacists, this means they should know the biologic sex for performing calculations such as creatinine clearance and to prevent teratogenic agents from reaching a transgender or transsexual man who could be pregnant or is capable of becoming pregnant. Promoting knowledge of transgender health issues will enable pharmacists to provide better, more holistic care to their transgender patients.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Ohio</li></region></list><tree><country name="États-Unis"><region name="Ohio"><name sortKey="Bishop, Bryan M" sort="Bishop, Bryan M" uniqKey="Bishop B" first="Bryan M." last="Bishop">Bryan M. Bishop</name></region><name sortKey="Bishop, Bryan M" sort="Bishop, Bryan M" uniqKey="Bishop B" first="Bryan M." last="Bishop">Bryan M. Bishop</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D89 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000D89 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= StressCovidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:984FBAFEAB0F1039C9CB16FEEA603ECD8A3A3ABA
|texte= Pharmacotherapy Considerations in the Management of Transgender Patients: A Brief Review
}}
| This area was generated with Dilib version V0.6.33. |  |